Biohaven starts pivotal Phase 3 trial of BHV-1300 in Graves' disease

Biohaven Ltd.

Biohaven Ltd.

BHVN

0.00
  • Biohaven began a pivotal Phase 3 trial of BHV-1300 in Graves’ disease, marking the first patient enrolled on June 29, 2026.
  • Prior early-stage results were already presented; the Phase 3 study will test whether treatment can restore normal thyroid function without standard antithyroid drugs.
  • BHV-1300 is positioned as a disease-modifying approach that removes the antibody driving Graves’ disease, shifting focus away from suppressing or destroying the thyroid.
  • The randomized, double-blind, placebo-controlled trial plans to enroll about 300 adults, with dosing designed for at-home self-injection.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606290730PR_NEWS_USPR_____NE93758) on June 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.